文献速递心力衰竭与心肌病冠心病血脂与心血管预防

早期慢性肾脏病中的心衰前状态:临床流行病学与治疗

Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.
PubMed 文献 · Eur Heart J · 2026-01-01

慢性肾脏病(CKD)影响全球10%-15%成人,是心衰的独立危险因素。在CKD G1-G3期尤其伴白蛋白尿时,即使eGFR轻度下降也与亚临床心脏异常相关,许多患者符合B期心衰(心衰前状态)标准。超声心动图和心脏磁共振是早期诊断工具,但常规筛查不推荐;控制危险因素及具有心肾获益的药物可指导心衰预防。

要点

  • CKD G1-G3期尤其伴白蛋白尿时,即使eGFR轻度下降也与亚临床心脏异常相关。
  • 许多CKD患者符合B期心衰(心衰前状态)标准,但症状非特异且生物标志物受肾脏清除影响。
  • 超声心动图和心脏磁共振是敏感诊断工具,但常规筛查不推荐;SGLT2抑制剂等具心肾获益药物可指导预防。

核心结论

  • 早期CKD(G1-G3期)尤其伴白蛋白尿时,即使eGFR轻度下降也与亚临床心脏异常相关,许多患者符合B期心衰框架。

研究设计与样本

  • 原文为综述,未报告系统检索范围与样本量。

主要发现

  • CKD影响全球10%-15%成人,是包括心衰在内的心血管疾病的强独立危险因素。
  • 在CKD G1-G3期尤其KDIGO A2-A3期,即使eGFR轻度下降也与左室肥厚、向心性重构、左室舒张功能障碍、射血分数保留的心衰及心律失常相关。
  • 许多CKD患者基于结构功能心脏改变和生物标志物升高且无症状,符合B期心衰(心衰前状态)标准。
  • 症状非特异且循环生物标志物受肾脏清除率下降干扰,使检测具有挑战性。
  • 超声心动图(包括斑点追踪技术)和心脏磁共振(组织表征和应变分析)是早期诊断和风险分层的敏感工具,但目前不推荐对无症状CKD患者常规筛查。

关键数值与推荐

  • CKD按KDIGO指南定义为持续≥3个月的肾脏结构或功能异常,包括eGFR下降和/或白蛋白尿。
  • CKD分期G1-G3,白蛋白尿分期A2-A3。

临床怎么用

  • 对早期CKD患者应积极控制传统和CKD特异性危险因素。
  • 具有心肾获益证据的药物包括SGLT2抑制剂、finerenone、利尿剂、肾素-血管紧张素系统阻滞剂和部分GLP-1受体激动剂,可指导心衰预防。
  • 超声心动图和心脏磁共振可用于早期诊断和风险分层,但不推荐对无症状CKD患者常规筛查。

局限性

  • 原文未报告综述的检索范围与纳入研究特征。
  • 常规筛查不推荐,早期诊断策略的成本效益有待研究。
  • 影像学和生物标志物在指导治疗中的作用尚需明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD), defined per the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines by persistent (≥3 months) abnormalities of kidney structure or function, including reduced estimated glomerular filtration rate (eGFR) and/or albuminuria, affects 10%-15% of adults worldwide and is a powerful, independent risk factor for cardiovascular diseases, including heart failure (HF). In CKD (stages G1-G3), particularly when accompanied by albuminuria (KDIGO stages A2-A3), even mild reductions in eGFR are associated with subclinical cardiac abnormalities-left ventricular hypertrophy, concentric remodelling, LV diastolic dysfunction, HF with preserved ejection fraction, and arrhythmias. Many CKD patients meet criteria for Stage B HF within the contemporary 'pre-HF' framework, based on structural and functional cardiac alterations and elevated biomarkers in the absence of symptoms. Detection is here challenging, as symptoms are non-specific and circulating biomarkers are confounded by reduced renal clearance. Echocardiography, including speckle-tracking techniques and emerging indices, and cardiac magnetic resonance imaging with tissue characterization and strain analysis are sensitive tools for early diagnosis and risk stratification, but routine screening is not currently recommended in asymptomatic CKD. This condition may be mitigated by aggressive control of traditional and CKD-specific risk factors, and therapies with proven cardiorenal benefits-SGLT2 inhibitors, finerenone, diuretics, renin-angiotensin system blockers, and selected GLP-1 receptor agonists-guide HF prevention. Future research should test cost-effective early diagnostic strategies, clarify the role of imaging and biomarkers in guiding therapy, and exploit multiomics and artificial intelligence to unravel mechanistic heterogeneity and enable personalized prevention of HF in early CKD.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zoccali C, De Caterina R, Tuttle KR, et al. Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment. Eur Heart J. 2026. PMID: 41914187. doi:10.1093/eurheartj/ehag220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。